Product Launch

Chicago – October 02, 2026 -- Setara Financial Corp. has advanced development of its Reference Layer, a benchmark and reference-data infrastructure designed to bring standardized measurement to the fragmented global compute market.

Compute market data remains scattered across hardware, providers and geographies

As artificial intelligence drives investment in GPUs, data centers, power and connectivity, compute has become a critical economic input, yet pricing and performance information remains fragmented across disconnected proprietary data sets. Setara's architecture starts with a governed data model built to standardize heterogeneous compute-market information before it enters benchmark calculation.

Plainsboro Township, N.J. – October 02, 2026 -- ConnX, Inc. is integrating Intel edge computing technology into its MaestroIQTM Shared Intelligence Layer, aiming to process operational data at the point of activity rather than in centralized data centers for transportation, manufacturing and other mission-critical operators.

ConnX pairs Intel Core Ultra Series 3 with MaestroIQ to correlate fragmented data streams

The combined architecture ingests and correlates signals from networks, applications, cybersecurity systems, vehicles and industrial assets. ConnX said the pairing lets its orchestration and industry application layer convert distributed infrastructure data into actionable intelligence in real time, rather than relying solely on centralized processing.

Washington – October 02, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is presenting three new data sets on its monoclonal antibody imsidolimab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, running September 30 through October 3, 2026.

Vanda shows imsidolimab cuts neutrophil levels rapidly in GPP patients

Poster P1769 (Abstract AS-4323) reports a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio following imsidolimab treatment in patients with generalized pustular psoriasis (GPP), a rare orphan skin condition.

Immunogenicity data on imsidolimab presented in separate poster

A second poster, P1784 (Abstract AS-2420), details the immunogenicity profile of imsidolimab in GPP patients.

Parsippany, N.J. – October 02, 2026 -- GAF, North America's largest roofing and waterproofing manufacturer, has expanded its partnership with the DoW SkillBridge program to offer a no-cost, six-month manufacturing training track for transitioning service members.

Manufacturers face a 3.8 million worker gap by 2033

The expansion responds to a labor shortage that Deloitte and The Manufacturing Institute project could leave nearly half of 3.8 million U.S. manufacturing positions unfilled by 2033, with industrial maintenance technicians among the highest-demand roles.

Ashland, Missouri – October 02, 2026 -- ABK Biomedical Inc. has launched construction of a commercial-scale manufacturing facility at Cartwright Business Park in Ashland, Missouri, designed to produce its Eye90 microspheres for liver cancer treatment. The groundbreaking, attended by Missouri Governor Mike Kehoe, follows the company's April announcement selecting Ashland for its long-term U.S. manufacturing base.

Facility targets commercial-scale output of yttrium-90 radioembolization device

The planned Good Manufacturing Practice (GMP) facility will be built for commercial-scale production of Eye90 microspheres, a clinical-stage yttrium-90 radioembolization device still under development for liver cancer treatment. The devices remain investigational and are not approved for use outside authorized clinical trials.

San Francisco – October 02, 2026 -- Constructor, a product discovery platform for ecommerce, has won the "Agentic Achievement" category at the MACH Alliance's 2026 MACH Impact Awards, citing a 900% year-over-year increase in companies deploying its conversational AI agents.

Retailers report measurable gains from agent deployments

Across customer deployments, Constructor's agentic technology has driven a 57% reduction in support requests, more than double the conversion rate versus standard search, 52% higher add-to-cart rates and 56% higher purchase rates among shoppers using an agent, according to the company.

Santa Cruz, Calif. – October 02, 2026 -- Emboline, Inc. completed the first commercial use of its Emboliner® Embolic Protection System in the United States on October 1, 2026, just weeks after receiving U.S. Food and Drug Administration 510(k) clearance.

Two TAVR procedures mark Emboline's commercial debut

The device was deployed during two transcatheter aortic valve implantation (TAVR) procedures performed by Tamim Nazif, MD, Co-Director of the Structural Heart and Valve Center at New York-Presbyterian/Columbia University Irving Medical Center. Dr. Nazif also serves as Co-Principal Investigator of the PROTECT H2H clinical trial, which evaluated the Emboliner's performance ahead of regulatory approval.

Palma de Mallorca, Spain – October 02, 2026 -- Smartee Denti-Technology concluded its first large-scale academic summit held outside China on September 19, drawing nearly 300 orthodontic clinicians from 27 countries to Palma de Mallorca and unveiling two new clear-aligner product systems for international markets.

Smartee debuts SA/SA Plus and AG KIDS systems at two-day event

The Smartee European Summit 2026 served as the international launch platform for Smartee SA/SA Plus, a clear-aligner system incorporating a locking mechanism to address primary snoring and mild-to-moderate obstructive sleep apnea alongside orthodontic treatment. The company also introduced Smartee AG KIDS, a craniofacial growth guidance system for patients aged 3 to 16 that targets sagittal, vertical and transverse growth management paired with orofacial myofunctional training appliances.

Cambridge, Mass. – October 02, 2026 -- Marengo Therapeutics will present interim results from its STARt-002 trial combining invikafusp alfa with Gilead's TRODELVY (sacituzumab govitecan-hziy) at the Society for Immunotherapy of Cancer's 41st Annual Meeting in Phoenix, Arizona, November 4-8, 2026.

STARt-002 pairs a T-cell agonist with an antibody-drug conjugate for the first time in clinical testing

The Phase 1b/2 study tests invikafusp alfa, a Vβ6-selective dual T-cell agonist, alongside TRODELVY's TROP2-directed cytotoxic payload delivery. Marengo's Chief Medical Officer Kevin Chin said the ADC is designed to release tumor antigens and inflame the tumor microenvironment, priming less immunogenic tumors for T-cell-mediated responses that invikafusp alfa can then amplify.

San Diego – October 02, 2026 -- Seasats has deployed a fleet of Lightfish unmanned surface vessels into the Gulf of America for persistent maritime border surveillance, expanding a federal autonomous maritime program run under the Office of the Assistant Secretary of War for Homeland Defense and Americas Security Affairs.

Lightfish fleet launches from Texas coast into Gulf waters

Launched from the Texas coast, the autonomous fleet will conduct continuous surveillance to detect drug trafficking and unauthorized vessel incursions in the Gulf, building on the company's prior support of Operation River Wall along the southern border.